Across TCGA pan-cancer cohorts, GPR176 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GPR176 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GPR176 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPR176 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
LUSC and SKCM are the cancer types where GPR176 Mutation most reproducibly stratifies survival.